Special purpose acquisition companies, or SPACs, have recently emerged onto the investment scene at a rapid rate. They are an unconventional means of taking a company public but becoming increasingly popular. Are SPACs really here to stay?
Every industry ground to a halt in March 2020 as COVID-19 swept the world. While some sectors were forced to shut down completely, clinical trial providers couldn’t simply stop. That would have meant years of research and funding gone to waste.
What do you want from diagnostics? Before COVID-19, this wouldn’t have been a question at the forefront of so many peoples' minds. However, now it is and consumers are demanding changes to the industry.
Demand for biologics is at an all-time high, which has forced businesses to majorly invest in manufacturing and production.
.jpg)
There’s optimism throughout all the markets we serve and to celebrate this we asked our CM Life Science team what they think we can expect from the year ahead in life sciences. Here's what they said...
COVID-19 has changed clinical trials forever. To find out how CROs have adapted to the global pandemic and whether this will have a lasting impact on the space, I spoke to two industry leaders.
We are undergoing the biggest vaccination program in history, aiming to finally bring the COVID-19 pandemic to an end. This presents pharmacovigilance’s with its biggest test yet.
.jpg)
With such a strong 2019, 2020 was expected to be a ‘mega year’ for life science companies with a reported $1.4 trillion in firepower at their disposal for M&As. However, COVID-19 gave us an unexpected twist.
To gain further insight into how labs have adapted, the CM Life Science team spoke to three North American market leaders in laboratory testing services about how they’ve supported the US healthcare system.
For this episode of CM Conversations, our Director of Operations Tom Maskill spoke with QIAGEN CEO Thierry Bernard.
In my line of work you come across new companies everyday, however, few are as forward-thinking and unique as Norman Health. I spoke to the company's founder and Managing Director, Jan-Wilem Eleveld.
.jpg)
The diagnostics space is doing crucial work to detect and limit the spread of Covid-19 all over the world – with companies both big and small contributing to the cause
.jpg)
The effect of COVID-19 has been huge with thousands of clinical trials interrupted forcing companies and sponsors to adapt. So, they have and the industry may never look the same again.
Coronavirus has provided us with a very large and extremely recent data set for research, patient populations and how different ethnic minorities are being affected versus the research. And the early indicators are that those from minority background
The approach to fighting coronavirus has not differed to the fight against any other outbreak in terms of what is required to control it.
One of the biggest partnering events in the life science calendar Bio-Europe Spring, was scheduled to take place in Paris from March 23 – 27 this year. That all changed with the emergence of COVID-19...
.jpg)
COVID-19 is one of the biggest challenges healthcare has ever faced. Crucial work is being done throughout molecular diagnostics to limit the spread in what many would call the space's finest hour.
It's humbling to see how the life science community has come together to combat the coronavirus. Here's what's happening in diagnostics.
